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Abstract
Background: Poor adherence to antidepressant therapy is an important barrier to the effective management of
major depressive disorder. This study aims to quantify the adherence rate to antidepressant treatment and to
determine the pattern of prescriptions of depressed patients in a psychiatric institute in Thailand.
Methods: This retrospective study used electronic pharmacy data of outpatients aged 15 or older, with a new
diagnosis of major depression who received at least one prescription of antidepressants between August 2005 and
September 2008. The medication possession ratio (MPR) was used to measure adherence over a 6 month period.
Results: 1,058 were eligible for study inclusion. The overall adherence (MPR > 80%) in those attending this facility
at least twice was 41% but if we assume that all patients who attended only once were non-adherent, adherence
may be as low as 23%. Fluoxetine was the most commonly prescribed drug followed by TCAs. A large proportion
of cases received more than one drug during one visit or was switched from one drug to another (39%).
Conclusions: Adherence to antidepressant therapy for treatment of major depression in Thailand is rather low
compared to results of adherence from elsewhere.
Background
Depressive disorders are associated with significant
health and social burden. In the Thai burden of disease
study in 2004, it ranked as one of the top ten causes of
Disability Adjusted Life Years (DALYs)[1]. Major
depressive disorder is recognized as a chronic episodic
disorder [2]. National treatment guidelines for major
depression recommend at least six months of continua-
tion therapy to prevent rel a p s ea n dr e c u r r e n c e[ 3 ] .
According to a review of non-adherence with antide-
pressant therapy, values of between 40% and 70% have
been reported for antidepressant therapy in developed
countries [4]. Non-adherence is associated with worse
clinical and economic outcomes in observational studies
[5,6].
There are no previous studies of adherence to antide-
pressants in Thailand. Only one retrospective study
shows the pattern of prescriptions for antidepressants in
53 new cases of major depressive disorder in the out-
patient psychiatric department of Siriraj hospital [7]. In
Thailand, most general practitioners are not confident
with the diagnosis of mental health conditions including
major depression. The majority of depressive patients
are treated in psychiatric hospitals and treatment cover-
age is low. According to an estimate from the Health
Information Technology Center of the Department of
Mental Health in Thailand only 3.4% of depressive
patients in 2005 received treatment from the Ministry of
Public Health including psychiatric hospitals and general
hospitals [8]. The purposes of this study are to measure
adherence to antidepressants and to determine the pat-
tern of antidepressant prescriptions for treatment of
major depression in a psychiatric institute in Thailand.
Methods
Data Source
This is a retrospective study using an electronic phar-
macy data set which contains demographic, diagnostic,
appointment and pharmacy information of outpatients
in Galyarajanagarindra Institute, a psychiatric hospital in
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Hospital Ethical Committee.
Study Population
Patients were eligible for inclusion in the study if they
were aged 15 and above and were newly diagnosed with
major depression using International Classification of
Diseases, Tenth Edition (ICD-10) codes as F32 (depres-
sive episode), F33 (recurrent depressive disorder), and
F38 (other mood/affective disorders)and F39 (unspeci-
fied mood/affective disorders). Inclusion into the study
required patients to have received at least one prescrip-
tion in these groups of antidepressants, namely tricyclic
antidepressants -TCAs (amitryptyline, nortryptyline and
imipramine), selective serotonin reuptake inhibitors
-SSRIs (fluoxetine, escitalopram, fluvoxamine, paroxitine
and sertaline) and other groups of antidepressants
(tianeptine, trazodone and venlafaxine).
Study Period
All patients were treated through the outpatient depart-
ment between 15
th August 2005 and 29
th September
2008. The date of the first prescription for any of the
antidepressants is defined as the index date. Data for
individual patients were analyzed in the 6- month period
following the index date. The 6-month timeframe was
chosen to reflect the minimum time in which the Amer-
ican Psychiatric Association (APA) guidelines recom-
mend patients be prescribed antidepressant therapy [9].
Definitions and Measurement of Adherence
This study used a definition of adherence, taken from
the conclusion reached by the participants at the World
Health Organization (WHO) Adherence meeting in June
2001 is “the extent to which the patient follows medical
instructions” [ 1 0 ] .T h e r ea r em a n yw a y st om e a s u r e
medication adherence. However, none are considered
the gold standard. Some suggest that the best way to
measure adherence is comparing multiple methods [11].
Recent reviews [12-14] of adherence measures showed
that the medication possession ratio (MPR) is a reliable
measure of adherence. We utilized pharmacy records
from databases to evaluate the MPR as a proxy for
adherence to antidepressants [12].
MPR was defined using the continuous, multiple-
interval medications available (CMA) methodology [15].
MPR is defined as the number of days for which the
drug has been supplied during the follow-up period
divided by the number of days elapsed during the per-
iod. From our dataset, the days of supply are calculated
as dosage strength divided by daily dose and multiplied
with the number of pills dispensed. For instance, a pre-
scription for fluoxetine 40 mg/day, sixty 20-mg tablets,
was calculated as (20/40) × 60 = 30 days’ supply.
For patients who attended only once, we assume
non-adherence as typical treatment should involve a
6-month course of antidepressants. Based on several
studies on adherence measures in the psychiatric and
medical literature, MPR < 0.8 represents non-adherence
and 0.8≤ MPR≤ 1.0 represents adherence [12,16-18]. In
the event that MPR was greater than 1.0, which
reflected patients refilling antidepressants before the end
of their medication supply or hoarding mediation for
later use, the MPR value was truncated at 1.
Results
There were 1,120 patients (6,025 visits) who were diag-
nosed with a depressive episode and received at least
one antidepressant prescription. We excluded 62 patients
who had missing age or were aged less than 15 years
old. This left 1,058 eligible for study inclusion, 64%
females and 36% males. Their average age was 46 with a
range from 15 to 86 years. The majority of ICD-10 diag-
nostic codes for patients at first prescription were F32
-depressive episode (96.9%). There were few F38 and
F39 (unspecified and other mood disorder) diagnostic
codes (Table 1).
Two thirds of patients were prescribed fluoxetine
(Table 2). TCAs were the next most commonly pre-
scribed class of drugs, followed by other drugs and
other SSRIs.
Over the six-month period only 23% of patients (243
of the 1,058 cases) qualify as being adherent with a
MPR greater than 0.80. Excluding the 470 patients who
attended once only (we do not know if they continued
to receive treatment elsewhere) 41% of patients were
adherent and the overall MPR for those visiting more
than once was 0.66 (Table 3). One-third of these
patients received only one type of drug over the six
month follow-up period and 30% were adherent.
Adherence in the 22% of patients who received two
drugs during the same visit was 62% and in the 45% of
patients who were switched from one drug to another
adherence was 39%.
Table 1 Distribution of depression diagnosis of patients
at first prescription
Diagnosis Patients (%)
(N = 1,058)
Depressive episode (not otherwise specified): F32, F32.8
and F32.9
34.1
Mild depressive episode: F32.0 5.8
Moderate depressive episode: F32.1 14.6
Severe depressive episode: F32.2 and F32.3 42.4
Recurrent depressive disorder: F33 0.0
Unspecified and other mood disorder: F38 and F39 3.1
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Our study was a retrospective analysis of pharmacy data.
The major strength of this form of analysis is that data
arise from a real life setting rather than clinical trials.
This is the first study to provide information on adher-
ence to antidepressants in Thailand and it indicates that
non-adherence is a problem for effective treatment of
major depression in Thailand.
Numerous direct and indirect methods for measuring
medication adherence are now available. MPR is an
established method used in the assessment of medica-
tion adherence in pharmacy data analyses. It is non-
invasive, easy to use and allows large numbers of patient
r e c o r d st ob ee x a m i n e d[ 1 9 ] .T h eM P Ri sc o n s i d e r e da
reasonable screening tool to determine patients with
poor adherence that may benefit from interventions that
aim to improve medication adherence [20].
A study of methods for evaluating patient adherence
to antidepressant therapy found no significant difference
in rates of 6-month antidepressant adherence between
three methods the MPR, length of therapy (LOT) and
combined MPR/LOT[12]. In addition, the MPR is a
proxy measure of adherence that is widely used in retro-
spective data analyses [13,14]. Hence, we used MPR in
our study.
The adherence in our study among patients attending
at least twice is similar to the MPR results from a
national database including data from patients who par-
ticipated in 30 different health plans reported in US stu-
dies [12,21]. According to mental health experts in
Thailand, the majority of cases are treated by psychiatric
services with only a few patients being treated in pri-
mary care. We do not know how many of the 44% of
patients who attended only once got further drug sup-
plies elsewhere but it is likely that many of them did
not. This means that the lower estimate of 23% adher-
ence is a more likely estimate than the 41% based on
more regular visitors. That would put adherence in
Thailand at quite a lower level than reported elsewhere.
Given the large proportion of patients who switch
between drug types, or are on multiple drug types, we
cannot calculate adherence for individual drugs. As has
been reported before, SSRIs are generally more tolerated
than TCAs, but evidence has been conflicting [22]. One
meta-analysis found a higher dropout rate for TCAs
compared with SSRIs [23], whereas another showed no
significant difference in the discontinuation rate between
SSRIs and TCAs [24]. Recently, there has been contrast-
ing evidence whether there is a difference in tolerability
between those antidepressants.
The pattern of antidepressant prescribing for major
depressive disorder is comparable to that found in an
out-patient psychiatric department of a university
affiliated hospital (Siriraj hospital) in Thailand [7]. That
study also showed greater use of SSRIs or new genera-
tion antidepressants than TCAs. The proportion of
patients who received multiple antidepressants was simi-
lar to a previous Thai study, with 23% receiving both
TCAs and SSRIs in the previous study and 22% receiv-
ing multiple drugs in our study.
There is controversy surrounding the use of combina-
tion antidepressant treatments. Proponents believe there
are combination medication options that are appropriate
for patients suffering treatment-resistant depression
(TRD) [25]. Opponents debate for possible toxicity and
drug interaction consequences. A survey in Australia
showed that nearly 80% of psychiatrists combine antide-
pressants [26]. However, 17% of respondents reported
serious complications from combination antidepressant
use such as epileptic seizures, hypomania and serotonin
syndrome.
According to experts in Thailand, combination anti-
depressant therapy is commonly used by specialists.
They would prefer to use a low dose of another antide-
pressant which has a sedative effect such as TCAs
(amitryptyline) combined with SSRIs (fluoxetine) over
the use of benzodiazepine for treatment of insomnia in
major depressive patients.
Table 2 Percentage of patients ever prescribed each drug
type
Drug group Percentage
1. TCAs (amitryptyline, imipramine and nortryptyline,
mianserin and mirtazapine)
43.8
2. Fluoxetine 67.4
3. Other SSRIs (escitalopram, fluvoxamine, paroxitine and
sertaline)
23.1
4. Others (tianeptine, trazodone and venlafaxine) 39.3
* Percentages add to greater than 100% as some patients received two
antidepressants concurrently or shifted from one drug to another during the
follow-up periods.
Table 3 Adherence to any antidepressants at 6 months across patterns of prescriptions
Pattern of prescriptions Cases %Adherent (95% CI) MPR
mean SE
1. Received only one drug 195 30 (24-36) 0.57 0.02
2. Ever received 2 drugs at the same date 130 62 (54-70) 0.83 0.02
3. Switched from initial drug to a different one 263 39 (34-45) 0.63 0.02
* Patients qualify as being adherent if MPR is greater than 0.80
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addressed. Firstly, several unverified assumptions
potentially limit the interpretation of adherence by
using the medication possession ratio, i.e. that 1)
patients are actually taking drugs every time they refill
their medications 2) patients do not receive medication
outside the hospital pharmacy network; and 3) the
MPR threshold of 0.8 is a valid threshold for adher-
ence. In other words, according to those assumptions,
the MPR can be overestimated if patients received
d r u g sb u tn o tt a k et h e mo ri tc a nb eu n d e r e s t i m a t e di f
they received antidepressants from other hospitals. As
mentioned previously, most non-adherent patients in
our study received only one prescription in this hospi-
tal and we do not know if these patients received sub-
sequent prescriptions at other facilities. For this reason
these patients were excluded from the MPR
calculation.
Secondly, the results should be interpreted with the
knowledge that medical adherence consists of both per-
sistence (time to continued prescription) and compli-
ance (obedience to follow the prescribed medication)
[12]. However, the MPR should be interpreted with cau-
tion, since this ratio provides insight into medication
adherence in terms of the proportion of time that the
patients had possession of drug, but no indication as to
the patterns of consistency of refilling. For example, in
patients who get the same MPR some might be more
consistent with refilling than others [27].
Lastly, there might be issues of generalisability as this
study was conducted based on data from only a psychia-
tric hospital and results may not be comparable to those
of patients in general hospitals.
Despite these limitations, non-adherence to antide-
pressant therapy is a problem in the management of
depression in Thailand. Our study is an early step in
establishing the MPR as a clinically useful way to esti-
mate adherence among individual patients. As we know,
factors that may affect adherence to medication fall into
several categories related to medication, patient, doctor
and other factors. The factors related to medication
treatment include number of medications taken and
side effects. The patient-related factors are educational
background, cognitive impairment, co-morbidities, per-
sonal beliefs, patient personality and psychosocial pro-
file. The doctor-related factors include doctor-patient
relationship including doctor-patient communication.
The examples for miscellaneous factors are healthcare
access and social support. Future qualitative research
could focus on the reasons for non-adherence and
investigate reasons why people only attend once. Such
studies would allow for a more accurate assessment of
patient adherence.
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